Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report
Open Access
- 6 February 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 16 (1), 1-13
- https://doi.org/10.1186/s12967-018-1382-1
Abstract
Cancer vaccines can effectively establish clinically relevant tumor immunity. Novel sequencing approaches rapidly identify the mutational fingerprint of tumors, thus allowing to generate personalized tumor vaccines within a few weeks from diagnosis. Here, we report the case of a 62-year-old patient receiving a four-peptide-vaccine targeting the two sole mutations of his pancreatic tumor, identified via exome sequencing. Vaccination started during chemotherapy in second complete remission and continued monthly thereafter. We tracked IFN-γ+ T cell responses against vaccine peptides in peripheral blood after 12, 17 and 34 vaccinations by analyzing T-cell receptor (TCR) repertoire diversity and epitope-binding regions of peptide-reactive T-cell lines and clones. By restricting analysis to sorted IFN-γ-producing T cells we could assure epitope-specificity, functionality, and TH1 polarization. A peptide-specific T-cell response against three of the four vaccine peptides could be detected sequentially. Molecular TCR analysis revealed a broad vaccine-reactive TCR repertoire with clones of discernible specificity. Four identical or convergent TCR sequences could be identified at more than one time-point, indicating timely persistence of vaccine-reactive T cells. One dominant TCR expressing a dual TCRVα chain could be found in three T-cell clones. The observed T-cell responses possibly contributed to clinical outcome: The patient is alive 6 years after initial diagnosis and in complete remission for 4 years now. Therapeutic vaccination with a neoantigen-derived four-peptide vaccine resulted in a diverse and long-lasting immune response against these targets which was associated with prolonged clinical remission. These data warrant confirmation in a larger proof-of concept clinical trial.Keywords
Funding Information
- Jürgen Manchot Foundation
- Stefan Morsch Foundation
This publication has 66 references indexed in Scilit:
- Current trends of anticancer immunochemotherapyOncoImmunology, 2013
- Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized TrialJournal of Clinical Oncology, 2013
- PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck CancerCancer Research, 2013
- Can the exome and the immunome converge on the design of efficient cancer vaccines?OncoImmunology, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trialsSurgery, 2011
- Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and miceJCI Insight, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Potential targets for pancreatic cancer immunotherapeuticsImmunotherapy, 2011
- Reliable prediction of T‐cell epitopes using neural networks with novel sequence representationsProtein Science, 2003